Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vale SA (VALE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Vale SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Vale SA trades at $14.46 (market cap $60.94B). The key difference: Vale SA is far larger — about 73.8× Amphastar Pharmaceuticals Inc's market cap, and Vale SA pays a 8.7% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | VALE | |
|---|---|---|
Market Cap | $826.08M | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $17.82 |
52-Week Low | $16.87 | $9.53 |
Enterprise Value | $1.22B | $77.86B |
Dividend Yield | — | 8.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
VALE trades at $14.46, up 1.69% with mixed earnings performance including a Q3 2025 beat but recent misses. Technical indicators show bearish momentum with oversold RSI signals. The company maintains solid cash flow generation ($2.42B net in 2025) despite declining profit margins from 42.85% in 2022 to 6.12% in 2025. Recent news highlights $2.56B decarbonization investments and governance developments.
VALE presents a cautious opportunity with analyst consensus at $17.50 (21% upside) but faces margin compression and debt increases. The stock's value proposition hinges on commodity price recovery and successful execution of efficiency initiatives amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
